Clinical Trials Logo

Acute GVHD clinical trials

View clinical trials related to Acute GVHD.

Filter by:
  • None
  • Page 1

NCT ID: NCT05263999 Recruiting - Clinical trials for Graft Versus Host Disease

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Start date: April 29, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids

NCT ID: NCT04645667 Completed - Acute GVHD Clinical Trials

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Start date: February 1, 2021
Phase:
Study type: Observational

The purpose of this research study is to evaluate tacrolimus plasma concentrations in patients who will undergo an allogeneic hematopoietic stem cell transplant (HCT). The study aims to identify associations between plasma concentrations, baseline demographic characteristics, clinical lab parameters, and genetic factors. These associations will help clinicians determine the best starting dose for tacrolimus in order to minimize risks of aGVHD and tacrolimus-induced toxicities.

NCT ID: NCT04373057 Recruiting - Acute GVHD Clinical Trials

Prebiotic Galacto-oligosaccharide and Acute GVHD

Start date: January 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the carbohydrate prebiotic (dietary supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria in the gut) and help prevent graft-versus host disease (GVHD) after allogeneic stem cell transplant. The study has two two parts. In phase 1, the best dose of GOS will be evaluated. In phase 2, using the best dose of GOS, participants will be randomized to receive GOS or a placebo (maltodextrin, a common food additive that is not known to affect the microbiome) so that the effect of GOS can be determined.

NCT ID: NCT03701698 Not yet recruiting - Acute GVHD Clinical Trials

Ruxolitinib and Steroid as First Line Therapy for Acute GVHD

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).

NCT ID: NCT02806947 Completed - Acute GVHD Clinical Trials

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up-front treatment for patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk stratification. This trial incorporates both a novel up front GVHD therapy (sirolimus) as well as a novel BMT CTN developed acute GVHD biomarker test.

NCT ID: NCT02631993 Completed - AML Clinical Trials

Photochemotherapy and Graft-versus-leukemia in Acute-leukemia

Start date: October 2014
Phase: N/A
Study type: Observational

Cure of leukemia after hematopoietic stem cell transplantation (HSCT) is sustained by the anti-leukemic effect of the grafted cells (graft-versus-leukemia (GVL)). However, it is not known whether the tumor-immunity is affected by photochemotherapy (psoralene photosensitization and ultraviolet light radiation) administered to attenuate graft-versus host disease (GVHD). The present study aim to investigate what happens to the GVL after photochemotherapy of aGVHD in a predominantly retrospective setting with 10-years follow-up after HSCT

NCT ID: NCT02611180 Recruiting - Clinical trials for Chronic Graft-versus-host Disease

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Start date: April 30, 2015
Phase:
Study type: Observational

Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.

NCT ID: NCT01530256 Terminated - Acute GvHD Clinical Trials

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

ALD518-010
Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.

NCT ID: NCT00350181 Completed - Leukemia Clinical Trials

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Start date: August 2006
Phase: Phase 2
Study type: Interventional

GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL